Instgra โ Dolutegravir 50 mg
Instgra is a highly effective antiretroviral medication for HIV treatment. Active ingredient: Dolutegravir (50 mg).
Manufacturer: Emcure Pharmaceuticals (India). Generic equivalent of Tivicay. It belongs to the class of Integrase Strand Transfer Inhibitors (INSTIs).
Why it is a preferred choice:
Instgra prevents the HIV virus from integrating its genetic material into human cells. It is recommended by the WHO as a first-line treatment due to its high barrier to genetic resistance and rapid viral suppression.
โ Benefits: Once-daily dosing, small tablet size, no need for pharmacokinetic boosting (Ritonavir).
Treatment of HIV-1 infection in adults and adolescents (aged 12+ and weighing at least 40 kg).
Must be used in combination with other antiretroviral agents (ART regimen).
Suitable for:
- Treatment-naive patients (starting therapy for the first time).
- Treatment-experienced patients (switching due to side effects or resistance).
Standard Dosage: One tablet (50 mg) once daily.
โ ๏ธ CRITICAL INTERACTION WARNING (Antacids & Vitamins):
Dolutegravir binds to cations (Aluminum, Magnesium, Calcium, Iron). If you take multivitamins, antacids, or laxatives:
- ๐ Take Instgra at least 2 hours BEFORE or 6 hours AFTER these supplements.
- Failure to separate doses will drastically reduce drug absorption.
May be taken with or without food.
- Hypersensitivity to Dolutegravir.
- Co-administration with Dofetilide: Strictly prohibited due to potential life-threatening toxicity.
Note on Resistance: Patients with known resistance to Integrase Inhibitors may require a double dose (50 mg twice daily) โ consult your doctor.
Generally well-tolerated. Potential side effects include:
- Insomnia: Difficulty sleeping (try taking the dose in the morning).
- Headache.
- Weight gain (a known effect of modern INSTI-based regimens).
- Fatigue.
What Customers Say
No reviews yet
Your review can be the first!